Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Neuropeptides. 2018 Oct 26;72:65–74. doi: 10.1016/j.npep.2018.10.003

Figure 2. Effects of MPP or PHTPP Pretreatment on VMN Glycogen Metabolic Enzyme and Cell Type-Specific Monocarboxlyate Transporter Protein Expression in Hypoglycemic Female and Male Rats.

Figure 2.

Data show for OVX + E female and testes-intact male rats mean normalized VMN glycogen synthase (GS) [Panel A; female data at left, male data at right], glycogen phosphorylase (GP) [Panel B; female data at left, male data at right], astrocytic monocarboxylate transporter-1 (MCT1) [Panel C; female data at left, male data at right], and neuronal monocarboxylate transporter-2 (MCT2) [Panel D, female data at left, male data at right] protein O.D. measures ± S.E.M. for treatment groups consisting of vehicle-pretreated eu-and hypoglycemic rats and ER antagonist-pretreated hypoglycemic animals. *p<0.05; **p<0.01; **p<0.001.